Barclays Boosts Axon Enterprise (NASDAQ:AXON) Price Target to $381.00

Axon Enterprise (NASDAQ:AXON) had its price target boosted by Barclays from $308.00 to $381.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. TheStreet lowered Axon Enterprise from a b rating to a c+ rating in a research report on Tuesday, February 27th. Robert W. Baird boosted their price objective on shares of Axon Enterprise from $260.00 to $300.00 and gave the stock an outperform rating in a research report on Thursday, February 22nd. JPMorgan Chase & Co. raised their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an overweight rating in a research report on Thursday, April 11th. Argus assumed coverage on shares of Axon Enterprise in a research report on Wednesday, March 13th. They set a buy rating and a $380.00 price target on the stock. Finally, StockNews.com downgraded shares of Axon Enterprise from a buy rating to a hold rating in a research note on Thursday, March 14th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $333.08.

Axon Enterprise Stock Down 0.3 %

Axon Enterprise stock opened at $311.86 on Wednesday. The firm has a market capitalization of $23.53 billion, a price-to-earnings ratio of 135.59 and a beta of 0.91. The company’s 50 day simple moving average is $310.82 and its 200 day simple moving average is $267.44. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.00 and a quick ratio of 2.66. Axon Enterprise has a fifty-two week low of $175.37 and a fifty-two week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Monday, May 6th. The biotechnology company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.20. The company had revenue of $460.74 million for the quarter, compared to analysts’ expectations of $441.57 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The business’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same period last year, the firm posted $0.51 earnings per share. As a group, sell-side analysts anticipate that Axon Enterprise will post 2.44 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Axon Enterprise by 15.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 82,347 shares of the biotechnology company’s stock worth $25,765,000 after acquiring an additional 10,718 shares during the last quarter. Fortis Capital Advisors LLC acquired a new position in Axon Enterprise in the 1st quarter valued at $351,000. Barings LLC grew its holdings in shares of Axon Enterprise by 6.6% during the 1st quarter. Barings LLC now owns 2,305 shares of the biotechnology company’s stock worth $721,000 after purchasing an additional 143 shares in the last quarter. Motley Fool Asset Management LLC increased its position in shares of Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock worth $153,981,000 after purchasing an additional 346,838 shares during the period. Finally, Avantax Advisory Services Inc. increased its position in shares of Axon Enterprise by 0.8% in the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 40 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.